EC Number   |
Application |
Reference |
|---|
   3.4.21.112 | degradation |
S1P reduces the size of the luminal domain to prepare ATF6 to be an optimal S2P substrate |
669270 |
| 3.4.21.112 | medicine |
a female patient with a heterozygous missense mutation in the transmembrane domain of S1P (Pro1003Ser) displays episodic, activity-induced, focal myoedema and myalgias with hyperCKemia. The clinical phenotype includes gastrointestinal hypomotility, ocular migraines, and polycystic ovary syndrome. The mutation leads to increased activation of protein response and lipid and cholesterol regulatory pathways and localization of S1P Pro1003Ser in the Golgi |
754742 |
| 3.4.21.112 | medicine |
glycoprotein cleavage by S1P is a promising target for the development of novel anti-arenaviral strategies |
710345 |
| 3.4.21.112 | medicine |
in fibroblasts of mucolipidosis type II mice and Niemann-Pick type C patients characterized by aberrant cholesterol accumulation, the proteolytic cleavage of the alpha/beta-subunit precursor of N -acetylglucosamine-1-phosphotransferase is not impaired |
754362 |
| 3.4.21.112 | medicine |
S1P is a potential target for indirect-acting pan-serotypic anti-dengue virus agents |
755140 |
| 3.4.21.112 | medicine |
S1P plays an integral role in skeletal development. S1P activity is necessary for a specialized endoplasmic reticulum stress response required by chondrocytes for the genesis of normal cartilage and thus endochondral ossification |
687906 |
| 3.4.21.112 | medicine |
SKI-1/S1P processing is strictly required for incorporation of viral glycoproteins. SKI-1/S1P may represent a promising antiviral target |
688727 |
| 3.4.21.112 | medicine |
small-molecule S1P inhibitors are capable of reducing cholesterol and fatty acid synthesis in vivo and, therefore, represent a potential new class of therapeutic agents for dyslipidemia and for a variety of cardiometabolic risk factors associated with diabetes, obesity, and the metabolic syndrome |
699750 |
| 3.4.21.112 | medicine |
the enzyme is a potential target for melanoma therapy |
732292 |
| 3.4.21.112 | medicine |
useful role of SKI-1/S1P in controlling cholesterol synthesis, particularly in the presence of endoplasmic reticulum stress. SKI-1/S1P inhibition may be a potential tool for the treatment of alcohol-induced liver steatosis |
686333 |
